Analysts Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) Target Price at $11.00

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been assigned a consensus recommendation of “Buy” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $11.00.

AQST has been the subject of a number of research reports. Leerink Partners boosted their price objective on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a report on Friday, December 20th. Finally, Cantor Fitzgerald began coverage on Aquestive Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price target on the stock.

Aquestive Therapeutics Trading Down 0.7 %

Shares of NASDAQ AQST opened at $2.97 on Friday. Aquestive Therapeutics has a twelve month low of $2.24 and a twelve month high of $6.23. The stock has a fifty day simple moving average of $3.41 and a 200-day simple moving average of $4.21. The stock has a market capitalization of $270.80 million, a PE ratio of -6.60 and a beta of 2.67.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. EntryPoint Capital LLC lifted its position in shares of Aquestive Therapeutics by 475.7% during the fourth quarter. EntryPoint Capital LLC now owns 135,797 shares of the company’s stock worth $483,000 after purchasing an additional 112,210 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Aquestive Therapeutics by 1.9% during the 4th quarter. Vanguard Group Inc. now owns 4,346,754 shares of the company’s stock worth $15,474,000 after buying an additional 82,958 shares during the last quarter. Intech Investment Management LLC grew its position in shares of Aquestive Therapeutics by 120.0% in the 4th quarter. Intech Investment Management LLC now owns 39,677 shares of the company’s stock worth $141,000 after acquiring an additional 21,645 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Aquestive Therapeutics in the 4th quarter valued at approximately $498,000. Finally, Charles Schwab Investment Management Inc. lifted its stake in Aquestive Therapeutics by 3.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 210,669 shares of the company’s stock worth $750,000 after purchasing an additional 7,129 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.